Ariel Pablos-Méndez
Directeur/Membre du Conseil chez Global Alliance for TB Drug Development
Profil
Ariel Pablos-Méndez has held director positions at the Global Alliance for TB Drug Development and ILiAD Biotechnologies LLC.
Postes actifs de Ariel Pablos-Méndez
| Sociétés | Poste | Début |
|---|---|---|
Global Alliance for TB Drug Development
 Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | Directeur/Membre du Conseil | - |
ILiAD Biotechnologies LLC
 ILiAD Biotechnologies LLC BiotechnologyHealth Technology ILiAD Biotechnologies LLC operates as a clinical stage biotechnology company, focuses on the prevention and treatment of disease caused by Bordetella Pertussis. It offers BPZE1, a live-attenuated pertussis vaccine that has completed Phase 1 human clinical trial. The company was founded by Keith Rubin in 2012 and is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | Health Technology |
ILiAD Biotechnologies LLC
ILiAD Biotechnologies LLC BiotechnologyHealth Technology ILiAD Biotechnologies LLC operates as a clinical stage biotechnology company, focuses on the prevention and treatment of disease caused by Bordetella Pertussis. It offers BPZE1, a live-attenuated pertussis vaccine that has completed Phase 1 human clinical trial. The company was founded by Keith Rubin in 2012 and is headquartered in New York, NY. | Health Technology |
